Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial.
Saved in:
| Title: | Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial. |
|---|---|
| Authors: | Melero I; Clinica Universidad de Navarra, CIMA and CIBERONC, Pamplona, Spain.; Nuffield Department of Medicine, University of Oxford, Oxford, UK., Reis B; Pharma Research and Early Development, Early Development Oncology, Roche Innovation Center Basel, Basel, Switzerland. bernhard.reis@roche.com., Rusterholz C; Pharma Research and Early Development, Early Development Oncology, Roche Innovation Center Basel, Basel, Switzerland., Epp A; Pharma Research and Early Development, Early Development Oncology, Roche Innovation Center Munich, Penzberg, Germany., Kratochwil NA; Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland., Wu C; Roche (China) Holding, Shanghai, China., Hettich M; Pharma Research and Early Development, Early Development Oncology, Roche Innovation Center Basel, Basel, Switzerland., Kazantzidis G; Roche Data Science and Statistics, Biostatistics Oncology, Basel, Switzerland., Rieder N; Pharma Research and Early Development, Early Development Oncology, Roche Innovation Center Munich, Penzberg, Germany., Schwalie PC; Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland., Badillo S; Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland., Kumpesa N; Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland., Thommen A; Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland., Vugts DJ; VU University Medical Center Amsterdam, Amsterdam, Netherlands., Moreno V; START Madrid-FJD, Hospital Fundacion Jimenez Diaz, Madrid, Spain., Lostes Bardaji J; Vall d'Hebron Institut d'Oncologia, Barcelona, Spain., Alvarez EC; Clinica Universidad de Navarra, Madrid, Spain., de Andrea CE; Clinica Universidad de Navarra, CIMA and CIBERONC, Pamplona, Spain., Spanggaard I; Rigshospitalet, Copenhagen, Denmark., Lee DH; University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea., Spicer J; King's College London, Guy's Hospital, London, UK., Thistlethwaite F; The Christie NHS Foundation Trust and University of Manchester, Manchester, UK., Oh DY; Seoul National University Hospital, Seoul, Korea., Hollebecque A; Gustave Roussy, Villejuif, France., Cirovic O; Pharma Research and Early Development, Early Development Oncology, Roche Innovation Center Basel, Basel, Switzerland., Symeonides SN; Edinburgh Cancer Centre, NHS Lothian & Edinburgh Experimental Cancer Medicine Centre, University of Edinburgh, Edinburgh, UK. |
| Source: | Nature cancer [Nat Cancer] 2026 May; Vol. 7 (5), pp. 840-856. Date of Electronic Publication: 2026 May 01. |
| Publication Type: | Journal Article; Clinical Trial, Phase I; Multicenter Study |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101761119 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2662-1347 (Electronic) Linking ISSN: 26621347 NLM ISO Abbreviation: Nat Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 42067656 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Melero+I%22">Melero I</searchLink>; Clinica Universidad de Navarra, CIMA and CIBERONC, Pamplona, Spain.; Nuffield Department of Medicine, University of Oxford, Oxford, UK.<br /><searchLink fieldCode="AU" term="%22Reis+B%22">Reis B</searchLink>; Pharma Research and Early Development, Early Development Oncology, Roche Innovation Center Basel, Basel, Switzerland. bernhard.reis@roche.com.<br /><searchLink fieldCode="AU" term="%22Rusterholz+C%22">Rusterholz C</searchLink>; Pharma Research and Early Development, Early Development Oncology, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Epp+A%22">Epp A</searchLink>; Pharma Research and Early Development, Early Development Oncology, Roche Innovation Center Munich, Penzberg, Germany.<br /><searchLink fieldCode="AU" term="%22Kratochwil+NA%22">Kratochwil NA</searchLink>; Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Wu+C%22">Wu C</searchLink>; Roche (China) Holding, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Hettich+M%22">Hettich M</searchLink>; Pharma Research and Early Development, Early Development Oncology, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Kazantzidis+G%22">Kazantzidis G</searchLink>; Roche Data Science and Statistics, Biostatistics Oncology, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Rieder+N%22">Rieder N</searchLink>; Pharma Research and Early Development, Early Development Oncology, Roche Innovation Center Munich, Penzberg, Germany.<br /><searchLink fieldCode="AU" term="%22Schwalie+PC%22">Schwalie PC</searchLink>; Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Badillo+S%22">Badillo S</searchLink>; Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Kumpesa+N%22">Kumpesa N</searchLink>; Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Thommen+A%22">Thommen A</searchLink>; Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Vugts+DJ%22">Vugts DJ</searchLink>; VU University Medical Center Amsterdam, Amsterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Moreno+V%22">Moreno V</searchLink>; START Madrid-FJD, Hospital Fundacion Jimenez Diaz, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Lostes+Bardaji+J%22">Lostes Bardaji J</searchLink>; Vall d'Hebron Institut d'Oncologia, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Alvarez+EC%22">Alvarez EC</searchLink>; Clinica Universidad de Navarra, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22de+Andrea+CE%22">de Andrea CE</searchLink>; Clinica Universidad de Navarra, CIMA and CIBERONC, Pamplona, Spain.<br /><searchLink fieldCode="AU" term="%22Spanggaard+I%22">Spanggaard I</searchLink>; Rigshospitalet, Copenhagen, Denmark.<br /><searchLink fieldCode="AU" term="%22Lee+DH%22">Lee DH</searchLink>; University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.<br /><searchLink fieldCode="AU" term="%22Spicer+J%22">Spicer J</searchLink>; King's College London, Guy's Hospital, London, UK.<br /><searchLink fieldCode="AU" term="%22Thistlethwaite+F%22">Thistlethwaite F</searchLink>; The Christie NHS Foundation Trust and University of Manchester, Manchester, UK.<br /><searchLink fieldCode="AU" term="%22Oh+DY%22">Oh DY</searchLink>; Seoul National University Hospital, Seoul, Korea.<br /><searchLink fieldCode="AU" term="%22Hollebecque+A%22">Hollebecque A</searchLink>; Gustave Roussy, Villejuif, France.<br /><searchLink fieldCode="AU" term="%22Cirovic+O%22">Cirovic O</searchLink>; Pharma Research and Early Development, Early Development Oncology, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Symeonides+SN%22">Symeonides SN</searchLink>; Edinburgh Cancer Centre, NHS Lothian & Edinburgh Experimental Cancer Medicine Centre, University of Edinburgh, Edinburgh, UK. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101761119%22">Nature cancer</searchLink> [Nat Cancer] 2026 May; Vol. 7 (5), pp. 840-856. <i>Date of Electronic Publication: </i>2026 May 01. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Clinical Trial, Phase I; Multicenter Study – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Publishing+Group%22">Nature Publishing Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101761119 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2662-1347 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2226621347%22">26621347 </searchLink><i>NLM ISO Abbreviation: </i>Nat Cancer <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42067656 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1038/s43018-026-01157-8 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 840 Titles: – TitleFull: Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Melero I – PersonEntity: Name: NameFull: Reis B – PersonEntity: Name: NameFull: Rusterholz C – PersonEntity: Name: NameFull: Epp A – PersonEntity: Name: NameFull: Kratochwil NA – PersonEntity: Name: NameFull: Wu C – PersonEntity: Name: NameFull: Hettich M – PersonEntity: Name: NameFull: Kazantzidis G – PersonEntity: Name: NameFull: Rieder N – PersonEntity: Name: NameFull: Schwalie PC – PersonEntity: Name: NameFull: Badillo S – PersonEntity: Name: NameFull: Kumpesa N – PersonEntity: Name: NameFull: Thommen A – PersonEntity: Name: NameFull: Vugts DJ – PersonEntity: Name: NameFull: Moreno V – PersonEntity: Name: NameFull: Lostes Bardaji J – PersonEntity: Name: NameFull: Alvarez EC – PersonEntity: Name: NameFull: de Andrea CE – PersonEntity: Name: NameFull: Spanggaard I – PersonEntity: Name: NameFull: Lee DH – PersonEntity: Name: NameFull: Spicer J – PersonEntity: Name: NameFull: Thistlethwaite F – PersonEntity: Name: NameFull: Oh DY – PersonEntity: Name: NameFull: Hollebecque A – PersonEntity: Name: NameFull: Cirovic O – PersonEntity: Name: NameFull: Symeonides SN IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 05 Text: 2026 May Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 2662-1347 Numbering: – Type: volume Value: 7 – Type: issue Value: 5 Titles: – TitleFull: Nature cancer Type: main |
| ResultId | 1 |
